The ESMO Sarcoma and Rare Cancers Congress 2025 programme is now online!
The ESMO Sarcoma and Rare Cancers Congress 2025 will provide insights into the diagnosis, prognostication, management and ongoing research of patients with rare adult solid cancers. Specifically, the Congress will include educational and scientific sessions covering:
- State-of-the-art multidisciplinary management of patients affected by the 10 families of rare solid tumours, as defined by the European Reference Networks (ERNs)
- Insights into the biology, molecular classification and diagnostics of sarcomas and rare cancers
- Latest original scientific research data
- Precision therapeutics for rare cancers and some rare molecular subgroups of common cancers
- Research methodological, policy and advocacy issues focusing on rare cancers
Learning objectives
- To familiarise practicing oncologists with the diagnosis, prognosis, care and follow up of patients with rare cancers
- To update experts on the latest breakthroughs in diagnostics and precision therapeutics in sarcomas and rare adult solid tumours
- To update oncologists on the latest breakthroughs in novel technologies, diagnostics and precision therapeutics in sarcomas and rare tumours
- To highlight ongoing scientific research breakthroughs and facilitate collaboration and networking
Accreditation
ESMO-MORA: The ESMO Sarcoma and Rare Cancers Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.